GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Price-to-Owner-Earnings

Pharma Equity Group A/S (OCSE:PEG) Price-to-Owner-Earnings : (As of Jun. 12, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Price-to-Owner-Earnings?

As of today (2024-06-12), Pharma Equity Group A/S's share price is kr0.261. Pharma Equity Group A/S does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Pharma Equity Group A/S's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Pharma Equity Group A/S was 370.00. The lowest was 0.00. And the median was 0.00.


OCSE:PEG's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.645
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-12), Pharma Equity Group A/S's share price is kr0.261. Pharma Equity Group A/S's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.03. Therefore, Pharma Equity Group A/S's PE Ratio for today is At Loss.

As of today (2024-06-12), Pharma Equity Group A/S's share price is kr0.261. Pharma Equity Group A/S's EPS without NRI for the trailing twelve months (TTM) ended in was kr-0.03. Therefore, Pharma Equity Group A/S's PE Ratio without NRI for today is At Loss.

During the past 13 years, Pharma Equity Group A/S's highest PE Ratio without NRI was 17.83. The lowest was 0.00. And the median was 0.00.


Pharma Equity Group A/S Price-to-Owner-Earnings Historical Data

The historical data trend for Pharma Equity Group A/S's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Price-to-Owner-Earnings Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Price-to-Owner-Earnings

For the Biotechnology subindustry, Pharma Equity Group A/S's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Price-to-Owner-Earnings falls into.



Pharma Equity Group A/S Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Pharma Equity Group A/S's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.261/-0.02
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group A/S  (OCSE:PEG) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Pharma Equity Group A/S Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.